

Slide 13




 Pyuria

 9. Stelle pyuria is urine which contains while blood cells while appearing stelle by standard culturing challending stelle by standard culturing incentions while blood cells while appearing stelle by standard culturing incentions while being stelled as a side effect from some incention in the stelle by uring is listed as a side effect from some incention is used as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a side effect from some incention is a social stelled as a social


Slide 14




Slide 17












Slide 20



Slide 23

Microbial Spectrum

- 75%–95% of cases of uncomplicated cystitis and pyelonephritis are caused Escherichia coli
- The balance are caused by other species of Enterobacteriaceae
- Proteus mirabilis
- Klebsiella pneumoniae • Staphylococcus saprophyticus

Slide 21



Slide 24

Resistance

- In evaluating choice of empiric antimicrobial therapy for uncomplicated UTIs, local antimicrobial susceptibility patterns of *E. coli* in particular should be considered.
 The resistance patterns of *E. coli* strains
- causing uncomplicated UTI varies
 considerably between regions and countries.
 What does this really mean for our well-travelled
- students?



Slide 26

The Resistance Continues

 Local resistance rates reported in hospital antibiograms are often skewed by cultures of samples obtained from inpatients or those with complicated infection

They may not predict susceptibilities in women with uncomplicated community-acquired infection.
 Resistance rates tend to be lower in this group.

Slide 29

So why does Nitrofurantoin still work?

- The preserved in vitro susceptibility of E. coli to nitrofurantoin, fosfomycin, and mecilinam over many years of use suggests these antimicrobials cause only minor collateral damage.
- cause only minor colladeral damage. The mechanism is thought to be these drugs' minimal effects on normal fecal flora. In contrast, increased rates of antimicrobial resistance have been demonstrated for antimicrobials that affect the normal fecal flora more significantly. Such as: timethoprim, timethoprim-sulfamethoxazole, quinolones, and ampicillin

Slide 27



Slide 30

And the winner is...


- Nitrofurantoin monohydrate/macrocrystals (100 mg twice daily for 5 days) • Minimal resistance
- Minimal propensity for collateral damage
- Efficacy comparable to 3 days of trimethoprim-sulfamethoxazole





What about that Fosfowhatsis stuff? • Fosfomycin trometamol (Monurol) (3 g in a single dose) An appropriate choice for therapy where it is available Minimal resistance • Minimal propensity for collateral damage • But it appears to have inferior efficacy compared with standard short-course regimens





Slide 33



Slide 36

Case #1

- + urgent urination + painful urination. No frequent urination and No blood in urine.
 Treated 2 weeks ago and still having soreness and itching. Urine is cloudy. Completed medication but symptoms never completely resolved.
 No mid-back pain, No vorniling, and No fever.
 + vaginal discharge (white). No abdominal pain.
 Treated for yeast 97/11.
 + Are you sexually active + unprotected intercourse (prior to last menses. No unprotected collus since menses). No possible pregnancy

Slide 37

ROUSE - Routine Urinalysis					
Test Name	Result	Flag(s)	Reference Range	Reported Date	Footnote
U COLOR	Yellow	1.000000	Straw-Yellow	9/22/2011 9:15 AM	44
U CLARITY	SiCloudy	A	Clear		
U GLUCOSE	Trace		Negative	9/22/2011 9:15 AM	
U BILIRUBIN	Negative		Negative	9/22/2011 9:15 AM	
U KETONE	Trace	A	Negative mg/dL	9/22/2011 9:15 AM	u.
U SPECIFIC GRAVITY	>=1.030	A	1.010 - 1.025	9/22/2011 9:15 AM	u.
U BLOOD	Large	A	Negative	9/22/2011 9:15 AM	LL.
UPH	6.0		5.0-8.5	9/22/2011 9:15 AM	44.
U UROBILINOGEN	0.2		0.2-1.0 EU/DL	9/22/2011 9:15 AM	LL
U NITRITE	Positive	A	Negative	9/22/2011 9:15 AM	LL.
U LEUKOCYTES	Moderate	•	Negative	9/22/2011 9:15 AM	u
U PROTEIN	>=300	A	Negative mg/dL	9/22/2011 9:15 AM	u
U WBC	>100	Α	None /HPF	9/22/2011 9:15 AM	LL.
U RBC	>100	A	None /HPF	9/22/2011 9:15 AM	LL.
U EPITEHLIAL	Fen	٨	None /LPF	9/22/2011 9:15 AM	u
U BACTERIA	3+	A	Negative /LPF	9/22/2011 9:15 AM	LL
NUCOUS	2+	A	None /LPF	9/22/2011 9:15 AM	LL.

Slide 40

ROUS8 - Routine Urinalysis			
Test Name	Result	Flag(s)	Reference Range
U COLOR	Yellow	- al	Straw-Yellow
U CLARITY	SICloudy	A	Clear
U GLUCOSE	Negative	1 100 100 100	Negative
U BILIRUBIN	Negative		Negative
UKETONE	Trace	A	Negative mg/dL
U SPECIFIC GRAVITY	>=1.030	A	1.010 - 1.025
UBLOOD	Moderate	A	Negative
UPH	6.0		5.0-8.5
U UROBILINOGEN	0.2	-	0.2-1.0 EU/DL
UNITRITE	Negative	1	Negative
U LEUKOCYTES	Moderate	A	Negative
U PROTEIN	30	A	Negative mg/dL
U WBC	>100	A.	None /HPF
URBC	>100	A	None /HPF
U EPITEHLIAL	Many	A	None /LFF
U BACTERIA	2+	A	Negative /LPF

Slide 38

UR1574 -	IC CU			
Test Na		Result		ference Range
PRELIM	ENARY	Microbiology	results A	
	Riebsiells p Gusceptibilt Ampioillin Ceftriazone Cephsiothin Ciproflozacin Eevoflozacin Nitrofuranto Borflozacin Teinech/Jolf	ty Test t	flebajelja go	Punchise S S S S S S S S S S S S S S S S S S S

Slide 41


Patient Education

• Self care

* Fluids – push them ©
 * Pyridium/Uristat – tell the patient about SE
 * Take all the medication

*Follow-up - #1important ! If worsen If no change

Slide 39



NURSE D	SURIA VISIT	
SUBJECT		
LMP		
**	brequent unmation	
* =	urgent unnation	
#E	painful unnation	
#3	blood in unner	
< Ether	auf Norre =	
жe	mid back pain	
10	unting	
(H) (H)	hear .	
~ Enter	aut here -	
	abdommal pam	
H E	vagnuli docharge	
- Enter	sut here -	
ЭE	Are you sexually active	
HE	possible pregnancy	
*=	unprotected intercourse	
Ownet	Authoral of Farth Covernal	
	have you had your symplems?	

Slide 43

Current	Method of Birth Control	
How lon	g have you had your symptoms?:	
	u used any type of self-treatment?:	
	text here >	
±=	history of gonorrhea	
11	history of chiamydia	
ΞE	history of herpes	
#=	history of diabetes	
	history of chronic illness	
(H) = 1	history of kidney infection	
	history of more than 3 urinary infections in the past 6 months	
< Enter	text here >	
Medical	louin .	
Allergie		
Dellaratio	4	
-	distant was designed as a second second	
Cast Ma	dical/Family/Social History	
< Enter	text here >	

rearing once	lignature: <u>Click here to sic</u>	22)		
	ONSULT			
	reviewed Turnalysis	result reviewed		
Assessment		UTI unlikely Cother (please note below)	
< Enter text he			presses right access	
LABUNN	Culture, in-House			
RxMacrob	e 100 MG Capeule; TAKE	T CAPSULE TWICE A	DAY X S DAYS; S DAY	IS, GTY 10 Capsule; O REP
F RuBectrim	DS 800-160 MG Tablet, 1	TABLET EVERY 12 HO	URS FOR 3 DAYS: 3	DAYS; GTY 6 Tablet; 0 RE
RaCiprofe	acin HCI 250 MG Tablet	1 TABLET TWICE A DA	Y X 3 DAYS: INDEF	DAYS, OTY & Tablet, 9 REP
Other				
Other: - Enter text he				
< Enter text he Clinician Signa	ture: Click here to sign			
< Enter text he Clinicien Signa Remainber to				
< Enter text he Clinicien Signa Remainber to	ture: Click here to sign			
< Enter text he Clinician Signa Remember to Orders	ture: Click here to sign	g on Orders link below.		

Slide 44

OBJECTIVE Vitals Cuff size: Cuff size: C Pediatric C Small Aduit C Regular Aduit C Large Aduit C Thigh T BP elevated (systolic >140 OR disatolic >90) Cornell Gannett Health Services < Enter text here > Targeted Exam Urinalysis Specific Gravity: C < or = 1.005 C = or > 1.010 Urinalysis results: C all normal C abnormalities present Pregnancy Test: C Negative C Positive clear Procedures

Slide 47

Slide 46

Gannett Health Services Utilization Review 2010

Analysis of the Costs Associated with Diagnosis and Treatment of Female Patients seen by Nursing for the complaint of Dysuria

Time frame June 2007 - may 2008 and June 2008 - May 2009
 Purpose: to develop new guidelines for dysuria

Slide 45



Slide 48

Sample testing scenarios


• 1. Urinalysis with micro \$27.00


• 2. Urinalysis with reflex to micro \$30.00

• 3. Urinalysis with reflex micro and culture and sensitivity \$145 .00















Slide 54


Slide 53

Why we looked at UTI data

- We see many patients every week with urinary symptoms. Anecdotally, we seemed to prescribe antibiotics without using strict criteria.
- Nurses often manage UTI walk-in patients.









Positive Cultures

- 50 cultures were positive for 1 or more organism.
 31 of the positive cultures grew out E. Coli (62%)
 6 of the 31 (19%) E. Coli cultures were resistant to bactrim
 No other organisms (19/50) were bactrim-resistant
- All 8 patients that were nitrite positive on dipstick had positive cultures



Positive Cultures	
 9 patients with positive cultures were not empirically treated with antibiotics. 	
 Presenting symptoms were either minimal, or urine dip was negative for LE, blood and nitrite. 	
 All patients were recalled when the culture results came back 	
 2 had resolved spontaneously, 	
• 7 were treated with appropriate antibiotics.	



Slide 62

Adverse Events


- I patient developed a rash on bactrim and was switched to cipro (and had a negative culture)
 I patient developed nausea and
- vomiting on bactrim and was switched to cipro (and also had a negative culture)

Slide 65

Practice Changes cont'd

- If a urine dip is positive for LE and blood, and the patient is symptomatic, treat empirically. Do not send culture.
- For patients who were empirically treated and return with symptoms within 30 days, a urine culture is sent, and treatment given if above criteria are met.

Slide 63



Duration of the second secon

Slide 67


UTI Follow	UTI Follow Up						
	used to repeat th November 1, 200						
o Diagnoses/Ur	ine Dips/Cultures	:					
	4/20/07 – 10/31/07	11/1/07 - 4/30/08					
# of visits	91	87					
# of UDips	86 (95%)	75 (86%)					
	83 (91%)	53 (61%)					
# of UCx	00 (0170)	33 (01 //)					



Slide 68

Did the previous practice changes make a difference? • Number of cultures being sent: • Reduced from 91% of visits to 61% • Number of antibiotic prescriptions being written: • Unchanged • Bactrim Resistance • Increased from 19% to 33%





Slide 69

Further practice changes to be instituted • To further reduce number of cultures being sent (especially no growth cultures): o No culture will be sent if dip is positive for blood only or is negative. o Schedule provider appointment.

- If UDip has trace or small LE, send cx and do not treat until cx results back.
- If UDip has moderate or large LE, do not send cx and treat with antibiotics.

UTI Furthe	r Follo	w Up			
 The QI evaluation has been repeated annually (data from 6 month intervals have been combined to reflect 12 month intervals). 					
	5/1/07 – 4/30/08	5/1/08 - 4/30/09	5/1/09 – 4/30/10	5/1/10 – 4/30/11	
Total number of visits	178	175	182	181	
Number of urine dips	161 (90%)	175 (100%)	181 (99%)	180 (99%)	
Number of urine cultures	136 (76%)	82 (45%)	82 (45%)	100 (55%)	
Number of antibiotic prescriptions	129 (72%)	100 (57%)	121 (66%)	118 (65%)	
				,	

Slide 73

No (Growth	n Cultur	es	
	5/1/07 – 4/30/07	5/1/08 – 4/30/09	5/1/09 – 4/30/10	5/1/10 – 4/30/11
No growth Culture	56 (43%)	49 (48%)	35 (43%)	60 (54%)
Antibiotic Rx	30 (54%)	11 (22%)	12 (34%)	18 (30%)

Improvements cont'd • Number of antibiotic prescriptions being written: Decreased from 72% of all visits to 65% of all visits. Fewer antibiotics were given to patients when the urine culture was subsequently negative (reduced from 54% to 30%). • There has been little variation in the number of antibiotics that are added after positive cultures come back (stable at 4.5%).

Slide 74

Positive	Cultur	es		
	5/1/07 – 4/30/08	5/1/08 – 4/30/09	5/1/09 – 4/30/10	5/1/10 – 4/30/11
Positive Cultures	77	54	46	50
E. Coli	52 (68%)	37 (69%)	33 (72%)	46 (92%)
Bactrim Resistant	13(25%)	5 (14%)	10 (30%)	12 (26%)
Cipro Resistant	n/a	0	5 (15%)	3 (7%)
Nitrofurantoin Resistant	n/a	n/a	n/a	1 (2%)

Slide 77

Slide 76

Improvements cont'd

- Antibiotic Resistance: Antibiotic Résistance:
 Having seen an increase in bactrim resistance to 33% after the first 2 series, our first line antibiotic was changed to cipro.
 We began to see a significant amount of cipro resistance (15%), and per IDSA guidelines have changed our first line antibiotic to nitrofurantoin.

Slide 75

Did our changes result in an improvement? • Number of cultures being sent: Reduced from 91% of visits in first 6 month cycle, to 76% in first year, and has decreased further to 55%.





Slide 80

• Study of college women with their first UTI

- 27 percent experienced at least one culture-confirmed recurrence within the six months following the initial infection
 2.7 percent had a second recurrence during this same time period
 When the first infection is caused by
- When the first infection is caused by Escherichia coli, women appear to be more likely to develop a second UTI within six months than those with a first UTI due to another organism

Slide 83

Behavioral risk factors cont'd

- Other risk factors identified were:
 Spermicide use during the past year
 Having a new sex partner during the past
- year • Having a first UTI at or before 15 years of
- age • Having a mother with a history of UTIs

Slide 81

